The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Atea Pharmaceuticals | Common Stock | 04683R106 | 52,315 | 847,208 | SH | SOLE | 847,208 | 0 | 0 | ||
Arcutis Biothereapeutics | Common Stock | 03969K108 | 18,048 | 623,836 | SH | SOLE | 623,836 | 0 | 0 | ||
Alpine Immune Sciences | Common Stock | 02083G100 | 13,620 | 1,284,900 | SH | SOLE | 1,284,900 | 0 | 0 | ||
Checkmate Pharmaceuticals | Common Stock | 162818108 | 16,208 | 1,335,050 | SH | SOLE | 1,335,050 | 0 | 0 | ||
Cidara Therapeutics | Common Stock | 171757107 | 5,334 | 2,005,249 | SH | SOLE | 2,005,249 | 0 | 0 | ||
ESSA Pharma | Common Stock | 29668H708 | 9,786 | 336,869 | SH | SOLE | 336,869 | 0 | 0 | ||
FibroGen | Common Stock | 31572Q808 | 4,535 | 130,646 | SH | SOLE | 130,646 | 0 | 0 | ||
Gossamer Bio | Common Stock | 38341P102 | 30,716 | 3,320,608 | SH | SOLE | 3,320,608 | 0 | 0 | ||
Ikena Oncology | Common Stock | 45175G108 | 63,538 | 2,249,123 | SH | SOLE | 2,249,123 | 0 | 0 | ||
Immunic | Common Stock | 4525EP101 | 28,503 | 1,788,160 | SH | SOLE | 1,788,160 | 0 | 0 | ||
Immunocore Holdings | Common Stock | 45258D105 | 2,194 | 51,535 | SH | SOLE | 51,535 | 0 | 0 | ||
Jounce Therapeutics | Common Stock | 481116101 | 2,830 | 275,513 | SH | SOLE | 275,513 | 0 | 0 | ||
Kronos Bio | Common Stock | 50107A104 | 111,761 | 3,818,283 | SH | SOLE | 3,818,283 | 0 | 0 | ||
Morphic Holding | Common Stock | 61775R105 | 143,802 | 2,272,478 | SH | SOLE | 2,272,478 | 0 | 0 | ||
ObsEva | Common Stock | H5861P103 | 3,248 | 999,364 | SH | SOLE | 999,364 | 0 | 0 | ||
Omega Alpha SPAC | Class A ordinary shares | G6749V107 | 5,000 | 501,000 | SH | SOLE | 501,000 | 0 | 0 | ||
Paratek Pharmaceuticals | Common Stock | 699374302 | 18,359 | 2,600,410 | SH | SOLE | 2,600,410 | 0 | 0 | ||
Pieris Pharmaceuticals | Common Stock | 720795103 | 580 | 225,741 | SH | SOLE | 225,741 | 0 | 0 | ||
Replimune Group | Common Stock | 76029N106 | 152,802 | 5,008,245 | SH | SOLE | 5,008,245 | 0 | 0 | ||
Spruce Biosciences | Common Stock | 85209E109 | 35,873 | 2,161,022 | SH | SOLE | 2,161,022 | 0 | 0 | ||
Syros Pharmaceuticals | Common Stock | 87184Q107 | 11,688 | 1,562,500 | SH | SOLE | 1,562,500 | 0 | 0 | ||
Trevi Therapeutics | Common Stock | 89532M101 | 3,424 | 1,263,408 | SH | SOLE | 1,263,408 | 0 | 0 |